{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigational+RSV+vaccine+2&page=2",
    "query": {
      "intervention": "Investigational RSV vaccine 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigational+RSV+vaccine+2&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigational+RSV+vaccine+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T09:29:36.746Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05045144",
      "title": "A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3(120 μg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Flu Quadrivalent influenza vaccine (15 μg HA)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1586,
      "start_date": "2021-10-26",
      "completion_date": "2022-06-06",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 5,
      "location_summary": "West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045144"
    },
    {
      "nct_id": "NCT03303625",
      "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Ad26.RSV.preF (1*10^11 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.RSV.preF (5*10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2017-11-29",
      "completion_date": "2020-04-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 1,
      "location_summary": "Newton, Kansas",
      "locations": [
        {
          "city": "Newton",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303625"
    },
    {
      "nct_id": "NCT02927873",
      "title": "A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV (GSK3389245A) low dose formulation vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV (GSK3389245A) middle dose formulation vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV (GSK3389245A) high dose formulation vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "12 Months to 23 Months"
      },
      "enrollment_count": 107,
      "start_date": "2017-01-11",
      "completion_date": "2020-11-26",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927873"
    },
    {
      "nct_id": "NCT04798001",
      "title": "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Meissa Vaccines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 130,
      "start_date": "2021-04-12",
      "completion_date": "2022-10-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798001"
    },
    {
      "nct_id": "NCT04732871",
      "title": "Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 OA investigational vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 1720,
      "start_date": "2021-02-15",
      "completion_date": "2027-02-19",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04732871"
    },
    {
      "nct_id": "NCT07628049",
      "title": "A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections+Metapneumovirus"
      ],
      "interventions": [
        {
          "name": "RSV/hMPV_V low dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_V medium dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_V high dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_W low dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_W medium dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_W high dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_X low dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_X medium dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV_X high dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV_Y low dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV_Y medium dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV_Y high dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV_Z low dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV_Z medium dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV_Z high dose vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1456,
      "start_date": "2026-06-05",
      "completion_date": "2029-04-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 3,
      "location_summary": "Stockbridge, Georgia • Lenexa, Kansas • Seattle, Washington",
      "locations": [
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07628049"
    },
    {
      "nct_id": "NCT06397768",
      "title": "Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RSV Immunization"
      ],
      "interventions": [
        {
          "name": "RSVt vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Streptococcus pneumoniae vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, mumps, and rubella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "6 Months to 12 Months"
      },
      "enrollment_count": 2226,
      "start_date": "2024-05-13",
      "completion_date": "2025-09-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Grand Bay",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06397768"
    },
    {
      "nct_id": "NCT05966090",
      "title": "A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 OA investigational vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HZ/su vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 530,
      "start_date": "2023-07-28",
      "completion_date": "2024-07-29",
      "has_results": true,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 11,
      "location_summary": "Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Corte Madera",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "North Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05966090"
    },
    {
      "nct_id": "NCT05059301",
      "title": "A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 OA investigational vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 770,
      "start_date": "2021-10-01",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 9,
      "location_summary": "Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Immokalee",
          "state": "Florida"
        },
        {
          "city": "Buford",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05059301"
    },
    {
      "nct_id": "NCT03814590",
      "title": "A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted medium dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) unadjuvanted high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Saline solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1053,
      "start_date": "2019-01-21",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-10T09:29:36.746Z",
      "location_count": 18,
      "location_summary": "Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814590"
    }
  ]
}